Announcing SOSV’s VC-Founder Robotics Matchup Dec 1-5
Announcing the 2025 Robotics VC-Founder Matchup, with meetings taking place online between Dec 1st (Monday) to Dec 5th (Friday). This virtual event will bring together 200+ startups and 200+ investors for 1:1 meetings online, scheduled at mutually convenient times, making it one of the largest robotics events. [Nov 23] Over 250 investors and 150 startups […]
Recent news
Helex Raises $3.5M Seed to Advance Non-Viral Gene Therapies for Kidney Diseases
A new hope for patients with genetic kidney diseases. Helex, an SOSV portfolio company and graduate of the IndieBio startup development program, which is developing a new class of targeted medicines for genetic kidney disorders, announced its $3.5M Seed round, led by pi Ventures, with participation from Bluehill Capital, SOSV, and others. Helex is tackling […]
Samphire Neuroscience Raises $5M Seed Round for Novel Neurotech Wearable Targeting Menstrual Pain
We’re thrilled to announce that Samphire Neuroscience, a graduate of our HAX hard tech startup development program, has secured $5 million Seed round led by Inventure VC with participation from Fortify Ventures. Earlier this year, the company launched Nettle—a CE-certified, non-hormonal neurotechnology device designed to relieve mental and physical symptoms tied to menstruation. Using gentle transcranial […]
Announcing SOSV’s VC-Founder Human Health Matchup – June 23-27, 2025 (Virtual, Free)
SOSV is hosting a completely free VC-Founder virtual matchmaking event focused on Health Tech. The 1:1 meetings will be taking place online between Monday, June 23 and Friday, June 27. 800+ startups | 400+ investors | 1 week of 1:1 meetings | Virtual | FreeThe largest event of its kind! Event Description The event is […]
IndieBio SF is hosting 3 events during SF Climate Week (April 21-25)
San Francisco Climate Week is around the corner, and the IndieBio team is gearing up for a dynamic week of thought-provoking conversations with leaders at the forefront of climate tech. We’re excited to invite you to three incredible events focused on the intersection of innovation, investment, and impact. Details below: 🤖 Breakthroughs in AI x […]
Announcing SOSV’s Biomanufacturing VC-Founder Matchup – April 21-25, 2025 (Virtual, Free)
Welcome to the Biomanufacturing Matchup Event, where biology meets bold ambition. EXPECTED > 200 startups | 200 investors | 1 week of virtual meetings | FreeUPDATE (APR.14) > There are already 250+ startups and 250+ investors registered! From sustainable jet fuel to protein production, from next-gen pharmaceuticals to high-performance biomaterials—there are few limits to what […]
IndieBio NY’s Demo Day Kickoff Video
SOSV’s IndieBio NY just held a demo day at its offices in Manhattan. Fifteen spectacular deep tech founders tackling human and planetary health took the stage in front of a packed audience of investors. The IndieBio NY team made this terrific video to kick off the event and introduce the main deep tech themes of […]
Meet Deborah Zajac, SOSV and IndieBio NY’s new General Partner
Introducing Deborah Zajac, SOSV’s newest general partner and member of the IndieBio NY team.
Oxyle has raised $16M to rid water supplies of Forever Chemicals (PFAS)
Zurich-based Oxyle recently raised a $16M seed round led by 360 Ventures with participation from Axeleo Capital, Founderful and SOSV, according to a report in Forbes. Water supplies around the world are contaminated with “Forever Chemicals,” or the 10,000 perfluoroalkyl and polyfluoroalkyl substances known by the acronym PFAS. They are linked to a sharp increases […]
Rybodyn Discovers Cryptic Human Proteome, Secures $4M for Novel Cancer Immunotherapy Advancements
Rybodyn, Inc. is making waves in biotech with its groundbreaking discovery of a cryptic human proteome and a $4 million pre-seed funding round.
Proton Intelligence closes a $6.95M seed round for continuous potassium monitoring
Proton Intelligence has raised a $6.95M seed round to accelerate their work on a continuous potassium monitor that aims revolutionize clinical care for at risk patients.